倾向性评分匹配研究:膈下与非膈下小肝癌TACE联合射频消融的疗效比较
回顾性纳入293例单个≤3 cm、不适合超声引导射频消融的肝细胞癌患者,接受碘油TACE联合后续射频消融,按肿瘤位置分为膈下组(99例)与非膈下组(194例),倾向性评分匹配后各93对。匹配队列中两组1、3、5年局部肿瘤进展率和总生存率均无显著差异(p=0.278和p=0.308),膈下位置不是LTP和OS的显著危险因素,并发症率无显著差异。结论认为联合TACE和RFA治疗小膈下HCC的疗效与非膈下HCC相似,似乎是有效安全的方法。
要点
- 膈下小HCC(≤3 cm)行TACE联合RFA的局部肿瘤进展和总生存与非膈下相似。
- 膈下位置不是局部肿瘤进展或总生存的独立危险因素。
- 两组并发症发生率无显著差异,联合治疗对膈下小HCC安全有效。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare therapeutic outcomes of combined transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) treatment for small hepatocellular carcinoma (HCC) in subphrenic versus nonsubphrenic locations by propensity score matching.
METHODS: This retrospective study included 293 patients with single HCC (≤ 3 cm) ineligible for ultrasound-guided RFA who received iodized oil TACE and subsequent RFA between June 2010 and January 2017. The patients were divided into two groups according to the tumor location: subphrenic (n = 99) and nonsubphrenic (n = 194). Subphrenic HCC was defined as a tumor abutting the diaphragm. Local tumor progression (LTP) and overall survival (OS) rates were compared by propensity score matching. Procedure-related complications were also assessed.
RESULTS: Matching yielded 93 matched pairs of patients. In the matched cohorts, cumulative 1-, 3-, and 5-year LTP rates were 5.4%, 12.1%, and 12.1% in the subphrenic group and 1.1%, 7.5%, and 8.6% in the nonsubphrenic group, respectively, with no significant differences (p = 0.278). Corresponding OS rates were 100%, 80.2%, and 71.3% in the subphrenic group and 97.9%, 88.1%, and 75.6% in the nonsubphrenic group, respectively, with no significant differences (p = 0.308). The subphrenic location was not a significant risk factor for LTP and OS in multivariate analysis. There were no significant differences in complication rates between the two groups (p > 0.05).
CONCLUSION: The therapeutic outcomes of combined TACE and RFA for small subphrenic HCC were similar to those for nonsubphrenic HCC. The combination therapy seems to be an effective and safe method in treating small subphrenic HCC.
引用
- Kim JG, Cho SK, Hyun D, et al. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study. Abdom Radiol (NY). 2021. PMID: 34581928. doi:10.1007/s00261-021-03291-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。